Insulin Delivery Devices Market Size To Reach $35.2 Billion By 2033

Insulin Delivery Devices Market Growth & Trends

The global insulin delivery devices market size is expected to reach USD 35.2 billion by 2033, registering a CAGR of 7.8% from 2026 to 2033, according to a new report by Grand View Research, Inc. Obesity, sedentary lifestyles, and unhealthy food habits, primarily in the young population, lead to the occurrence of diabetes. In addition, the growing diabetic geriatric population is another factor supporting the growth of this vertical. According to the United Nations, Department of Economic and Social Affairs, around 901 million individuals were aged 60 or over in 2015 and this number is projected to increase to 1.4 billion by 2030. Thus, the enlarging elderly population is expected to boost the demand for insulin delivery devices.

Technological innovations and advancements are an ongoing trend in this vertical. The high demand for advanced insulin delivery devices is supporting the adoption of recently launched innovative pen devices and portable pumps, which is estimated to boost the market growth. Also, favorable reimbursement policies for these devices, mainly in developed countries like the U.S. and Germany, are anticipated to fuel the market growth during the study period. However, stringent regulatory requirements regulating the approval of insulin delivery devices and the high cost of insulin analogs in diabetes care management are major factors restraining the growth of this industry.

The market's prominent competitors are taking different initiatives such as acquisition, funding, and product development to expand their product portfolio and enhance their manufacturing capacity. For instance, in October 2021, Eli Lilly partnered with Cipla, to market its Insulin products (Humalog and Trulicity) in India. Additionally, In June 2021, the company acquired Protomer Technologies, to strengthen its market presence. Further, Novo Nordisk, joined hands with Biocorp to develop a Bluetooth-enabled smart add-on device for their pen insulin injector.

 Request a free sample copy or view the report summary: Insulin Delivery Devices Market Report

Insulin Delivery Devices Market Report Highlights

• Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention

• The increasing adoption of connected diabetes management solutions is transforming the way insulin therapy is monitored and administered, with a strong focus on improving patient adherence and clinical outcomes.

• For instance, in January 2024, PharmaSens, a Switzerland-based company specializing in medical devices, has recently applied for FDA approval in the United States for its 'niia essential' insulin patch pump system.

• The industry is characterized by a moderate to high level of industry concentration, with a few major global players dominating the scene. These include companies such as Novo Nordisk, Sanofi, Eli Lilly, Medtronic, and Insulet Corporation.

• Regulatory approvals are crucial in the insulin delivery devices industry. The process can be lengthy and requires substantial evidence of safety and efficacy. Regulations can significantly impact the time-to-market of new devices.

• Insulin pens captured the largest market share of 43.7% in 2025. The dominance of insulin pens is primarily driven by their superior convenience, ease of use, and dosing accuracy compared to traditional vial-and-syringe methods, making them highly suitable for daily self-administration.

• The home care segment captured the largest revenue share of 48.2% in 2025. This segment plays a significant role in the insulin delivery devices market, providing patients with the convenience of managing their diabetes at home.

• North America insulin delivery devices market held the largest share of 40.7% in 2025 and is expected to maintain its dominance during the forecast period. Some key factors contributing to the region’s growth are the increasing geriatric population, the growing burden of diabetes due to lifestyle changes, the rising prevalence of obesity, and high treatment costs.

Insulin Delivery Devices Market Segmentation

Grand View Research has segmented the global insulin delivery devices market report on the basis of product, end use, and region:

Insulin Delivery Devices Product Outlook (Revenue, USD Million, 2021 - 2033)

• Insulin Pens

  • Reusable Insulin Pens

  • Disposable Insulin Pens

• Insulin Pumps

  • Tubed Pumps

    • Reusable Device/Components

    • Consumables

  • Tubeless Insulin Pumps

    • Reusable Device/Components

    • Consumables

• Insulin Pen Needles

  • Standard Pen Needles

  • Safety Pen Needles

• Insulin Syringes

• Others

Insulin Delivery Devices End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospitals & Clinics

• Homecare

• Others

Insulin Delivery Devices Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Insulin Delivery Devices Market

• Novo Nordisk A/S

• Sanofi

• Eli Lilly and Company

• Ypsomed AG

• Medtronic

• Insulet Corporation

• B. Braun SE

• Owen Mumford Ltd.

• Tandem Diabetes Care, Inc.

• BD (Becton, Dickinson and Company)